Date: 2016-09-07
Type of information: Nomination
Compound: chief executive officer
Company: Confo Therapeutics (Belgium)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On September 7, 2016, Confo Therapeutics announced the appointment of Cedric Ververken as CEO and board member, starting October 1. Dr. Ververken will lead the transition of Confo Therapeutics from a technology company to a drug development company.
- Cedric Ververken joins Confo Therapeutics from Ablynx, where he advanced through positions of increasing responsibility, most recently as Vice President Business Development heading the company’s partnering activities around specific products and Nanobody drug discovery collaborations with top tier pharmaceutical companies. He started his career as scientist-project manager heading cross functional R&D teams and advancing internal and partnered R&D programs. Dr. Ververken has a PhD in bioscience engineering from KU Leuven.
- Stephane van Rooijen, MD, MBA, who is stepping down as CEO, played a crucial role setting up the company and establishing its operations. He secured the initial funding, initiated a promising portfolio of drug development programs and recruited an outstanding team to move the organization to the next phase. With the appointment of the new CEO the company secures the successful transition of Confo Therapeutics into a drug discovery and development company.
Financial terms:
Latest news:
Is general: Yes
